Shanghai-based Sanyou Biopharmaceuticals Co., Ltd and KangaBio have entered into a licensing agreement, granting Kanga exclusive rights to research, develop, manufacture, and commercialize Sanyou’s in-house antibody drug candidate. Financial details of the deal were not disclosed.
Agreement Details
The agreement builds on a previous licensing term list for two of Sanyou’s monoclonal antibodies (mAbs). Beyond product authorization, the firms have collaborated on various R&D stages, including cooperative development, commissioned R&D, and technical services.
Support for Kanga
Sanyou will leverage its comprehensive antibody drug project services, flexible R&D technical services, and unique multi-channel production capabilities to support Kanga’s development efforts.-Fineline Info & Tech
